Months after $10M Series A, rare disease AI upstart Healx hauls in $56M in fresh funding

This July, the Cambridge, UK-based company raised $10 million in a Series A round of funding. On Wednesday, Healx unveiled a fresh $56 million injection — as it preps for a Phase IIa clinical trial expected to initiate in the first quarter of 2020 — in patients with Fragile X syndrome, a condition that spawns developmental problems and is considered the leading genetic cause of autism.